Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 42

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Staphylococcus aureus—A Known Opponent against Host Defense Mechanisms and Vaccine Development—Do We Still Have a Chance to Win?

Wójcik-Bojek, Urszula, Różalska, Barbara, Sadowska, Beata · 2022 · International Journal of Molecular Sciences

Abstract

The main purpose of this review is to present justification for the urgent need to implement specific prophylaxis of invasive Staphylococcus aureus infections. We emphasize the difficulties in achieving this goal due to numerous S. aureus virulence factors important for the process of infection and the remarkable ability of these bacteria to avoid host defense mechanisms. We precede these considerations with a brief overview of the global necessitiy to intensify the use of vaccines against other pathogens as well, particularly in light of an impasse in antibiotic therapy. Finally, we point out global trends in research into modern technologies used in the field of molecular microbiology to develop new vaccines. We focus on the vaccines designed to fight the infections caused by S. aureus, which are often resistant to the majority of available therapeutic options.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23020948

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 110

  1. Rosini, 2020, Vaccines against antimicrobial resistance, Front. Immunol., 11, 1048, 10.3389/fimmu.2020.01048 · DOI
  2. Excler, 2021, Supply and delivery of vaccines for global health, Curr. Opin. Immunol., 71, 13, 10.1016/j.coi.2021.03.009 · DOI
  3. Castro, 2021, A brief review on Group A Streptococcus pathogenesis and vaccine development, R. Soc. Open Sci., 8, 201991, 10.1098/rsos.201991 · DOI
  4. Ma, 2021, Pertactin-deficient Bordetella pertussis, vaccine-driven evolution, and reemergence of pertussis, Emerg. Infect. Dis., 27, 1561, 10.3201/eid2706.203850 · DOI
  5. Masomian, M., Ahmad, Z., Gew, L.T., and Poh, C.L. (2020). Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines, 8. · DOI
  6. Stuart, J.M. (2021). Editorial for the Special Issue: Bacterial meningitis—Epidemiology and vaccination. Microorganisms, 9. · doi:10.3390/microorganisms9050917
  7. Teymournejad, 2021, Evasion of immunological memory by S. aureus infection: Implications for vaccine design, Front. Immunol., 12, 633672, 10.3389/fimmu.2021.633672 · DOI · Paper page
  8. Flouchi, 2021, The relationship between nasal carriage of Staphylococcus aureus and surgical site infections in a Hospital Center in Morocco, Int. J. Microbiol., 2021, 5585588, 10.1155/2021/5585588 · doi:10.1155/2021/5585588
  9. Lin, J., Peng, Y., Xu, P., Zhang, T., Bai, C., Lin, D., Ou, Q., and Yao, Z. (2016). Methicillin-resistant Staphylococcus aureus nasal colonization in Chinese children: A prevalence meta-analysis and review of influencing factors. PLoS ONE, 11. · doi:10.1371/journal.pone.0159728
  10. Sakr, 2018, Staphylococcus aureus nasal colonization: An update on mechanisms, epidemiology, risk factors, and subsequent infections, Front. Microbiol., 9, 2419, 10.3389/fmicb.2018.02419 · DOI · Paper page
  11. Verhoeven, 2014, Detection and clinical relevance of Staphylococcus aureus nasal carriage: An update, Expert Rev. Anti. Infect. Ther., 12, 75, 10.1586/14787210.2014.859985 · DOI
  12. Dayan, 2016, Staphylococcus aureus: The current state of disease, pathophysiology and strategies for prevention, Expert Rev. Vaccines, 15, 1373, 10.1080/14760584.2016.1179583 · DOI
  13. Hoerr, 2018, S. aureus endocarditis: Clinical aspects and experimental approaches, Int. J. Med. Microbiol., 308, 640, 10.1016/j.ijmm.2018.02.004 · DOI
  14. Turner, 2019, Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research, Nat. Rev. Microbiol., 17, 203, 10.1038/s41579-018-0147-4 · DOI · Paper page
  15. Jensen, 2012, Predictors of mortality in Staphylococcus aureus bacteremia, Clin. Microbiol. Rev., 25, 362, 10.1128/CMR.05022-11 · DOI · Paper page
  16. Volkow, 2018, Bloodstream infection caused by S. aureus in patients with cancer: A 10-year longitudinal single-center study, Support. Care Cancer, 26, 4057, 10.1007/s00520-018-4275-1 · DOI
  17. Lu, 2021, Human MALT1 deficiency and predisposition to infections, Curr. Opin. Immunol., 72, 1, 10.1016/j.coi.2021.02.008 · DOI
  18. Otto, 2018, Staphylococcal biofilms, Microbiol. Spectr., 6, 1, 10.1128/microbiolspec.GPP3-0023-2018 · DOI · Paper page
  19. Schilcher, K., and Horswill, A.R. (2020). Staphylococcal biofilm development: Structure, regulation, and treatment strategies. Microbiol. Mol. Biol. Rev., 84. · DOI · Paper page
  20. Zheng, 2018, Colonization of medical devices by staphylococci, Environ. Microbiol., 20, 3141, 10.1111/1462-2920.14129 · DOI · Paper page
  21. Guo, 2020, Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus, Front. Cell Infect. Microbiol., 10, 107, 10.3389/fcimb.2020.00107 · DOI · Paper page
  22. Ippolito, 2010, Methicillin-resistant Staphylococcus aureus: The superbug, Int. J. Infect. Dis., 14, S7, 10.1016/j.ijid.2010.05.003 · DOI · Paper page
  23. Sakamoto, Y., Yamauchi, Y., Jo, T., Michihata, N., Hasegawa, W., Takeshima, H., Matsui, H., Fushimi, K., Yasunaga, H., and Nagase, T. (2021). In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: A matched-pair cohort study. BMC Pulm. Med., 21. · DOI
  24. Zhen, 2020, Clinical and economic impact of methicillin-resistant Staphylococcus aureus: A multicentre study in China, Sci. Rep., 10, 3900, 10.1038/s41598-020-60825-6 · DOI
  25. Costerton, 1999, Bacterial biofilms: A common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
  26. Flemming, 2016, Biofilms: An emergent form of bacterial life, Nat. Rev. Microbiol., 14, 563, 10.1038/nrmicro.2016.94 · DOI · Paper page
  27. Costerton, 2004, Bacterial biofilms: From the natural environment to infectious diseases, Nat. Rev. Microbiol., 2, 95, 10.1038/nrmicro821 · DOI · Paper page
  28. Hall, 2017, Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria, FEMS Microbiol. Rev., 41, 276, 10.1093/femsre/fux010 · DOI · Paper page
  29. Resch, 2005, Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions, Appl. Environ. Microbiol., 71, 2663, 10.1128/AEM.71.5.2663-2676.2005 · DOI · Paper page
  30. Sadowska, 2013, The immunomodulatory activity of Staphylococcus aureus products derived from biofilm and planktonic cultures, Arch. Immunol. Ther. Exp. (Warsz), 61, 413, 10.1007/s00005-013-0240-3 · DOI
  31. Bjarnsholt, 2010, Antibiotic resistance of bacterial biofilms, Int. J. Antimicrob. Agents, 35, 322, 10.1016/j.ijantimicag.2009.12.011 · DOI · Paper page
  32. Stewart, 2002, Mechanisms of antibiotic resistance in bacterial biofilms, Int. J. Med. Microbiol., 292, 107, 10.1078/1438-4221-00196 · DOI · Paper page
  33. Cheung, 2021, Pathogenicity and virulence of Staphylococcus aureus, Virulence, 12, 547, 10.1080/21505594.2021.1878688 · DOI · Paper page
  34. 2019, Immune evasion by Staphylococcus aureus, Microbiol. Spectr., 7, 1
  35. Pietrocola, 2017, Staphylococcus aureus manipulates innate immunity through own and host-expressed proteases, Front. Cell Infect. Microbiol., 7, 166, 10.3389/fcimb.2017.00166 · DOI · Paper page
  36. Flannagan, 2015, Antimicrobial mechanisms of macrophages and the immune evasion strategies of Staphylococcus aureus, Pathogens, 4, 826, 10.3390/pathogens4040826 · DOI · Paper page
  37. Shettigar, 2020, Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection, Eur. J. Clin. Microbiol. Infect. Dis., 39, 2235, 10.1007/s10096-020-03984-8 · DOI
  38. Rooijakkers, 2020, Staphylococci evade the innate immune response by disarming neutrophils and forming biofilms, FEBS Lett., 594, 2556, 10.1002/1873-3468.13767 · DOI
  39. Thammavongsa, 2015, Staphylococcal manipulation of host immune responses, Nat. Rev. Microbiol., 13, 529, 10.1038/nrmicro3521 · DOI · Paper page
  40. Rooijakkers, 2005, Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases, Nat. Immunol., 6, 920, 10.1038/ni1235 · DOI · Paper page
  41. Ko, Y.P., Kuipers, A., Freitag, C.M., Jongerius, I., Medina, E., van Rooijen, W.J., Spaan, A.N., van Kessel, K.P., Höök, M., and Rooijakkers, S.H. (2013). Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog., 9. · DOI
  42. Kang, 2013, Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway, J. Biol. Chem., 288, 20520, 10.1074/jbc.M113.454462 · DOI · Paper page
  43. Zhang, 2017, Staphylococcus aureus SdrE captures complement factor H’s C-terminus via a novel ‘close, dock, lock and latch’ mechanism for complement evasion, Biochem. J., 474, 1619, 10.1042/BCJ20170085 · DOI · Paper page
  44. Jusko, 2014, Staphylococcal proteases aid in evasion of the human complement system, J. Innate Immun., 6, 31, 10.1159/000351458 · DOI
  45. Singh, 2019, Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity, Med. Microbiol. Immunol., 208, 585, 10.1007/s00430-018-0573-y · DOI
  46. Guerra, 2017, Epic immune battles of history: Neutrophils vs. Staphylococcus aureus, Front. Cell Infect. Microbiol., 7, 286, 10.3389/fcimb.2017.00286 · DOI · Paper page
  47. Pidwill, 2021, The role of macrophages in Staphylococcus aureus infection, Front. Immunol., 11, 620339, 10.3389/fimmu.2020.620339 · DOI · Paper page
  48. Yamada, K.J., Heim, C.E., Xi, X., Attri, K.S., Wang, D., Zhang, W., Singh, P.K., Bronich, T.K., and Kielian, T. (2020). Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance. PLoS Pathog., 16. · DOI
  49. Mohamed, N., Timofeyeva, Y., Jamrozy, D., Rojas, E., Hao, L., Silmon de Monerri, N.C., Hawkins, J., Singh, G., Cai, B., and Liberator, P. (2019). Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States. PLoS ONE, 14. · DOI
  50. Nanra, 2013, Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus, Hum. Vaccin. Immunother., 9, 480, 10.4161/hv.23223 · doi:10.4161/hv.23223
  51. Cheng, A.G., McAdow, M., Kim, H.K., Bae, T., Missiakas, D.M., and Schneewind, O. (2010). Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog., 6. · DOI · Paper page
  52. Labate, 2018, Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion, Proc. Natl. Acad. Sci. USA, 115, 5564, 10.1073/pnas.1718104115 · DOI · Paper page
  53. Tam, 2019, Staphylococcus aureus secreted toxins and extracellular enzymes, Microbiol. Spectr., 7, 2, 10.1128/microbiolspec.GPP3-0039-2018 · DOI · Paper page
  54. Mandell, 1975, Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction, J. Clin. Investig., 55, 561, 10.1172/JCI107963 · DOI · Paper page
  55. Joo, 2015, Mechanisms of resistance to antimicrobial peptides in staphylococci, Biochim. Biophys. Acta., 1848, 3055, 10.1016/j.bbamem.2015.02.009 · DOI
  56. Flannagan, 2016, Intracellular replication of Staphylococcus aureus in mature phagolysosomes in macrophages precedes host cell death, and bacterial escape and dissemination, Cell Microbiol., 18, 514, 10.1111/cmi.12527 · DOI · Paper page
  57. Jubrail, 2016, Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages, Cell Microbiol., 18, 80, 10.1111/cmi.12485 · DOI
  58. Proctor, 2014, Staphylococcus aureus small colony variants (SCVs): A road map for the metabolic pathways involved in persistent infections, Front. Cell. Infect. Microbiol., 4, 99, 10.3389/fcimb.2014.00099 · DOI · Paper page
  59. Speziale, 2021, Staphylococcus aureus induces neutrophil extracellular traps (NETs) and neutralizes their bactericidal potential, Comput. Struct. Biotechnol. J., 19, 3451, 10.1016/j.csbj.2021.06.012 · DOI
  60. Missiakas, 2021, Selective host cell death by Staphylococcus aureus: A strategy for bacterial persistence, Front. Immunol., 11, 621733, 10.3389/fimmu.2020.621733 · DOI
  61. Berube, 2013, Staphylococcus aureus α-toxin: Nearly a century of intrigue, Toxins, 5, 1140, 10.3390/toxins5061140 · DOI · Paper page
  62. Daum, 2007, Community-acquired methicillin-resistant Staphylococcus aureus: The role of Panton-Valentine leukocidin, Lab. Investig., 87, 3, 10.1038/labinvest.3700501 · DOI · Paper page
  63. Darboe, 2019, Prevalence of Panton-Valentine leukocidin (PVL) and antimicrobial resistance in community-acquired clinical Staphylococcus aureus in an urban Gambian hospital: A 11-year period retrospective pilot study, Front. Cell Infect. Microbiol., 9, 170, 10.3389/fcimb.2019.00170 · DOI
  64. Graves, 2010, Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence, J. Mol. Med., 88, 109, 10.1007/s00109-009-0573-x · DOI
  65. Cheung, 2014, Phenol-soluble modulins--critical determinants of staphylococcal virulence, FEMS Microbiol. Rev., 38, 698, 10.1111/1574-6976.12057 · DOI · Paper page
  66. Surewaard, 2013, Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis, Cell Microbiol., 15, 1427, 10.1111/cmi.12130 · DOI · Paper page
  67. Berlon, 2015, Clinical MRSA isolates from skin and soft tissue infections show increased in vitro production of phenol soluble modulins, J. Infect., 71, 447, 10.1016/j.jinf.2015.06.005 · DOI
  68. Cruz, 2021, Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation, Proc. Natl. Acad. Sci. USA, 118, e2016772118, 10.1073/pnas.2016772118 · DOI
  69. Deis, 2014, Multiscale conformational heterogeneity in staphylococcal protein A: Possible determinant of functional plasticity, Structure, 22, 1467, 10.1016/j.str.2014.08.014 · DOI
  70. Pauli, 2014, Staphylococcus aureus infection induces protein A-mediated immune evasion in humans, J. Exp. Med., 211, 2331, 10.1084/jem.20141404 · DOI
  71. Goodyear, 2003, Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin, J. Exp. Med., 197, 1125, 10.1084/jem.20020552 · DOI · Paper page
  72. Krakauer, T. (2019). Staphylococcal superantigens: Pyrogenic toxins induce toxic shock. Toxins, 11. · DOI
  73. Paulsen, J., Mehl, A., Askim, Å., Solligård, E., Åsvold, B.O., and Damås, J.K. (2015). Epidemiology and outcome of Staphylococcus aureus bloodstream infection and sepsis in a Norwegian county 1996-2011: An observational study. BMC Infect. Dis., 15. · DOI
  74. Tuffs, S.W., Haeryfar, S.M.M., and McCormick, J.K. (2018). Manipulation of innate and adaptive immunity by staphylococcal superantigens. Pathogens, 7. · DOI
  75. Wójcik-Bojek, U., Rywaniak, J., Bernat, P., Podsędek, A., Kajszczak, D., and Sadowska, B. (2021). An in vitro study of the effect of Viburnum opulus extracts on key processes in the development of staphylococcal infections. Molecules, 26. · DOI
  76. Zhang, 2018, Master mechanisms of Staphylococcus aureus: Consider its excellent protective mechanisms hindering vaccine development!, Microbiol. Res., 212-213, 59, 10.1016/j.micres.2018.05.002 · DOI
  77. Nishitani, 2020, IsdB antibody–mediated sepsis following S. aureus surgical site infection, JCI Insight., 5, e141164, 10.1172/jci.insight.141164 · DOI
  78. Gurtman, 2019, The development of a Staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery, Hum. Vaccin. Immunother., 15, 358, 10.1080/21645515.2018.1523093 · DOI
  79. Mbaeyi, 2020, Meningococcal vaccination: Recommendations of the advisory committee on immunization practices, United States, 2020, MMWR Recomm. Rep., 69, 1, 10.15585/mmwr.rr6909a1 · DOI · Paper page
  80. Principi, N., and Esposito, S. (2016). Prevention of community-acquired pneumonia with available pneumococcal vaccines. Int. J. Mol. Sci., 18. · DOI
  81. Frenck, 2017, Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study, Vaccine, 35, 375, 10.1016/j.vaccine.2016.11.010 · DOI
  82. Nissen, 2015, A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults, Vaccine, 33, 1846, 10.1016/j.vaccine.2015.02.024 · DOI
  83. Creech, 2020, Persistence of immune responses through 36 months in healthy adults after vaccination with a novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag), Open Forum Inf. Dis., 7, 1
  84. Handke, L.D., Gribenko, A.V., Timofeyeva, Y., Scully, I.L., and Anderson, A.S. (2018). MntC-dependent manganese transport is essential for Staphylococcus aureus oxidative stress resistance and virulence. mSphere, 3. · DOI
  85. Miller, 2020, Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms, FEMS Microbiol. Rev., 44, 123, 10.1093/femsre/fuz030 · DOI · Paper page
  86. Venkatasubramaniam, 2021, Safety and immunogenicity of a 4-component toxoid-based Staphylococcus aureus vaccine in rhesus macaques, Front. Immunol., 12, 621754, 10.3389/fimmu.2021.621754 · DOI
  87. Raafat, 2019, Fighting Staphylococcus aureus biofilms with monoclonal antibodies, Trends Microbiol., 27, 303, 10.1016/j.tim.2018.12.009 · DOI
  88. Rupp, 2007, Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia, Antimicrob. Agents Chemother., 51, 4249, 10.1128/AAC.00570-07 · DOI
  89. Yu, X.Q., Robbie, G.J., Wu, Y., Esser, M.T., Jensen, K., Schwartz, H.I., Bellamy, T., Hernandez-Illas, M., and Jafri, H.S. (2016). Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob. Agents Chemother., 61. · DOI
  90. Chan, L.C., Chaili, S., Filler, S.G., Miller, L.S., Solis, N.V., Wang, H., Johnson, C.W., Lee, H.K., Diaz, L.F., and Yeaman, M.R. (2017). Innate immune memory contributes to host defense against recurrent skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Infect. Immun., 85. · DOI
  91. Chan, 2018, Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory, Proc. Natl. Acad. Sci. USA, 115, E11111, 10.1073/pnas.1808353115 · DOI
  92. Leentjens, 2018, Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis, Circ. Res., 122, 664, 10.1161/CIRCRESAHA.117.312465 · DOI
  93. Maher, 2013, Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection, Infect. Immun., 81, 4478, 10.1128/IAI.01026-13 · DOI
  94. Chan, 2015, Nonredundant roles of interleukin-17A (IL-17A) and IL-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistant Staphylococcus aureus, Infect. Immun., 83, 4427, 10.1128/IAI.01061-15 · DOI
  95. Dillen, 2018, Clonally expanded γδ T cells protect against Staphylococcus aureus skin reinfection, J. Clin. Investig., 128, 1026, 10.1172/JCI96481 · DOI
  96. Clegg, 2021, Staphylococcus aureus vaccine research and development: The past, present and future, including novel therapeutic strategies, Front. Immunol., 12, 705360, 10.3389/fimmu.2021.705360 · DOI · Paper page
  97. Rappuoli, 2021, Vaccinology in the post−COVID-19 era, Proc. Natl. Acad. Sci. USA, 118, e2020368118, 10.1073/pnas.2020368118 · DOI
  98. Ford, 2021, Antivirulence strategies for the treatment of Staphylococcus aureus infections: A mini review, Front. Microbiol., 11, 632706, 10.3389/fmicb.2020.632706 · DOI
  99. Klimka, 2021, Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase, Vaccines, 6, 11
  100. Bidmos, 2018, Bacterial vaccine antigen discovery in the reverse vaccinology 2.0 era: Progress and challenges, Front. Immunol., 9, 2315, 10.3389/fimmu.2018.02315 · DOI
  101. Ahmad-Mansour, N., Loubet, P., Pouget, C., Dunyach-Remy, C., Sotto, A., Lavigne, J.-P., and Molle, V. (2021). Staphylococcus aureus toxins: An update on their pathogenic properties and potential treatments. Toxins, 13. · DOI · Paper page
  102. Micoli, 2021, The role of vaccines in combating antimicrobial resistance, Nature Rev. Microbiol., 19, 287, 10.1038/s41579-020-00506-3 · DOI · Paper page
  103. Vekemans, 2021, Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: A World Health Organization action framework, Clin. Infect. Dis., 73, e1011, 10.1093/cid/ciab062 · DOI
  104. Medaglini, 2018, Innovation partnership for a roadmap on vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow, Vaccine, 36, 1136, 10.1016/j.vaccine.2017.11.069 · DOI
  105. Dijksteel, 2021, Review: Lessons learned from clinical trials using antimicrobial peptides (AMPs), Front. Microbiol., 12, 616979, 10.3389/fmicb.2021.616979 · DOI · Paper page
  106. Lee, J.-K., and Park, Y. (2020). All d-Lysine analogues of the antimicrobial Peptide HPA3NT3-A2 increased serum stability and without drug resistance. Int. J. Mol. Sci., 21. · DOI
  107. Ryu, 2014, Colonization and infection of the skin by S. aureus: Immune system evasion and the response to cationic antimicrobial peptides, Int. J. Mol. Sci., 15, 8753, 10.3390/ijms15058753 · DOI
  108. Speziale, P., and Pietrocola, G. (2021). Monoclonal antibodies targeting surface-exposed and secreted proteins from staphylococci. Vaccines, 9. · DOI
  109. Swolana, D., Kępa, M., Kabała-Dzik, A., Dzik, R., and Wojtyczka, R.D. (2021). Sensitivity of staphylococcal biofilm to selected compounds of plant origin. Antibiotics, 10. · DOI
  110. Walsh, 2021, Efficacy of phage- and bacteriocin-based therapies in combating nosocomial MRSA infections, Front. Mol. Biosci., 8, 654038, 10.3389/fmolb.2021.654038 · DOI

Cited by

Metadata

Authors
Wójcik-Bojek, U., Różalska, B., & Sadowska, B.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-01-16
Volume
23
Issue
2
Pages
948
ISSN
1422-0067
Cited by
42
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.